U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT06858280) titled 'Patiromer and Diet/hrQoL in Chronic Dialysis' on Feb. 27.
Brief Summary: This is a phase III, prospective, randomized, double-blind, placebo-controlled, single-center, pilot trial, aimed at assessing whether treatment with the oral potassium binder patiromer as compared to placebo allows withdrawal or down-titration of potassium dietary restriction without increasing the risk of hyperkalemia in chronic dialysis patients.
Study Start Date: June 15, 2025
Study Type: INTERVENTIONAL
Condition:
Hyperkalaemia
Chronic Kidney Disease Stage 3 and 4
Dietary Intervention
Intervention:
DRUG: Patiromer 8400 MG [Veltassa]
Randomized patien...